Abstract
Background: Patients who respond inadequately to standard regimens of controlled ovarian hyperstimulation (COH) are commonly treated with one of two regimens, including the micro-dose flare (MDF) and a combination of clomiphene citrate and human menopausal gonadotropin (CC/hMG). Both protocols stimulate folliculogenesis via endogenously produced as well as exogenously administered follicle-stimulating hormone (FSH), but whether higher FSH levels result in greater estradiol (E2) or number of oocytes has not been established.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
